Imunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer Treatment
Imunon, a pioneering biotechnology company, made history with its fourth quarter and full year 2025 financial results, showcasing a truly transformational year in the fight against ovarian cancer. The company's proprietary IL-12 immunotherapy, IMNN-001, has demonstrated unprecedented potential to redefine frontline treatment for women with newly diagnosed advanced ovarian cancer.
The OVATION 2 study, which evaluated the efficacy of IMNN-001 in combination with standard-of-care chemotherapy and PARP inhibitors as maintenance therapy, yielded remarkable results. Patients treated with this regimen showed a median overall survival increase of more than two years compared to those receiving only chemotherapy. This breakthrough finding has given Imunon's laser-focused execution of the ongoing Phase III trial a significant boost.
The OVATION 3 pivotal Phase III study is rapidly advancing, and the urgency of this program remains front and center for Imunon's efforts to create value for its shareholders and address the unmet need in ovarian cancer. Traditional chemotherapy has not advanced in over 30 years, making IMNN-001 a game-changer in this patient population.
The final overall survival readout from the OVATION 2 study demonstrated continued improvement across three different analyses conducted throughout the trial. Starting with the original Phase II clinical trial data readout in July 2024, which showed a median overall survival benefit of 11.1 months, subsequent clinical data readouts revealed significant improvements – first to 13 months in December 2024 and now to an impressive 14.7 months.
Imunon's President and Chief Executive Officer, Dr. Stacy Lindborg, underscored the company's strong momentum heading into 2026, citing its commitment to creating value for shareholders and addressing the pressing need in ovarian cancer. "Our proprietary IL-12 immunotherapy continues to demonstrate its potential to redefine frontline treatment for women with newly diagnosed advanced ovarian cancer," she said.
The company's R&D day, hosted in November in New York City, brought together leading clinicians and investors to highlight Imunon's ability to turn immunologically cold tumors hot, remodel the tumor microenvironment, and deliver meaningful clinical survival benefits to women with newly diagnosed advanced ovarian cancer. This innovative approach has the potential to revolutionize treatment options for patients and set a new standard in the fight against ovarian cancer.
